Completed PHASE2 INTERVENTIONAL NCT00123747

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer

A Phase II Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer

Sponsor: AHS Cancer Control Alberta

Conditions Lung Neoplasms

Interventions Positron Emission Tomography (PET) scan Imaging

Updated 5 times since 2017 Last updated: Feb 24, 2016 Started: Aug 31, 2005 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lung Neoplasms and is currently completed. AHS Cancer Control Alberta leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AHS Cancer Control Alberta
Cross Cancer Institute

Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada